Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (ASTRA)
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Sponsor: AstraZeneca
Terminated
Study was terminated based on the findings of primary analysis at 18 months post-RAI treatment. Patients pending 3 year follow up had end of study phone call.
Other terminated trials from AstraZeneca
Other Differentiated Thyroid Cancer trials with similar outcome
This PHASE3 trial investigates Differentiated Thyroid Cancer and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 17 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 12 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Sep 2019 — Nov 2020 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
May 2019 — Sep 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Augsburg, Germany , Aurora, United States , Barretos, Brazil , Birmingham, United States , Bordeaux, France , Boston, United States , Caen, France , Catania, Italy , Cincinnati, United States and 32 more locations